Alex Zhavoronkov, founder and CEO of Insilico Medicine, explores how A.I. is driving drug discovery breakthroughs—and ...

TPD technologies, particularly PROTACs and MGDs, represent a paradigm shift in drug development by completely eliminating ...

The era of digital twins offers a future where deep biology, AI and real-world data combine to make medicine more personal, ...

Impurities and instability are challenges for all drugs, but a growing range of technological tools are helping drug developers and manufacturers minimize them.

The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 ...

Insitro’s co-founder is betting on the fact that real progress in biotech requires more than clever algorithms.

A Seattle startup company has inked a deal with Eli Lilly to develop AI-powered cancer treatments. The team at Lila Biologics ...

Strategic collaboration sets a new standard for accelerating drug development through AI-driven insights. PHILADELPHIA, Sept.

The College of Natural Sciences welcomed more than a dozen new tenured and tenure-track faculty members in 2025.

ARM CEO Rene Haas believes the biggest potential for AI lies in healthcare, from accelerating drug discovery to curing diseases like cancer and Alzheimer’s. Since launching Stargate AI in January, ...

Newly launched ophthalmology company Ollin Biosciences has emerged onto the scene with $100 million in backing and a mission to bring a rival drug for wet age-related macular degeneration (AMD) that ...